VitaBreath. Helping your COPD patients remain active

Similar documents
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Chronic Obstructive Pulmonary Disease (COPD) Measures Document

Commissioning for Better Outcomes in COPD

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Chronic obstructive pulmonary disease

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Roflumilast (Daxas) for chronic obstructive pulmonary disease

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD)

Endobronchial valve insertion to reduce lung volume in emphysema

Chronic conditions and the high risk of falling

Living well with COPD

Chronic conditions and the high risk of falling

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600

How can research help to create more sustainable COPD services?

COPD Challenge CASE PRESENTATION

What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM

National COPD Audit Programme

About The National End of Life Care Intelligence Network

CoughAssist E70. More than just a comfortable cough. Flexible therapy that brings more comfort to your patients airway clearance

Managing Exacerbations of COPD (Version 3.0)

National COPD Audit Programme

BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults

Wales Primary Care COPD Audit

Respiratory Drug Delivery. Be inspired. Nebulizer and compressor catalog

Improving access to pulmonary rehabilitation through Medicare Benefit Scheme subsidies

Respiratory Medicine. Some pet peeves and other random topics. Kyle Perrin

Putting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)

Titration protocol reference guide

A simple solution for your complex patients

Changing Healthcare Forever mycopd

Resource impact report: Eating disorders: recognition and treatment (NG69)

CARE OF THE ADULT COPD PATIENT

Chronic Obstructive Pulmonary Disease, shortened to COPD, is an umbrella term for a group of conditions which cause long-term damage to the airways.

RESPIRATORY CARE IN GENERAL PRACTICE

Does this information apply to me? Information for the public Published: 1 June 2010 nice.org.uk

People living well with Dementia in the East Midlands: Improving the Quality of Care in Acute Hospitals

ACTIVE TAMESIDE STRATEGY, GROWTH AND DEVELOPMENT

Bi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients

South East Coast Operational Delivery Network. Critical Care Rehabilitation

Physiotherapy on the Intensive Care Unit. Information for patients, their family and carers

How to write bipap settings

NIV - BI-LEVEL POSITIVE AIRWAY PRESSURE (BIPAP)

BiPAPS/TVAPSCPAPASV???? Lori Davis, B.Sc., R.C.P.T.(P), RPSGT

Natural performance. Introducing the BiPAP A30 - because ease of use and therapy efficacy are key to patient well-being

Chronic Obstructive Pulmonary Disease

Pulmonary Rehabilitation in COPD-An Important Non-pharmacological Treatment

RESPIRATORY PROBLEMS IN MND RICHARD HARRISON MND RESPIRATORY ASSESSMENT SERVICE LUNG HEALTH UNIVERSITY HOSPITAL OF NORTH TEES

Paramedic Rounds. Pre-Hospital Continuous Positive Airway Pressure (CPAP)

NHS. Living-donor lung transplantation for end-stage lung disease. National Institute for Health and Clinical Excellence. Issue date: May 2006

St. John Chrysostom Federation

UNDERSTANDING COPD MEDIA BACKGROUNDER

Chronic Obstructive Pulmonary Disease. Information about medication and an Action Plan to use if your condition gets worse due to an infection

The Natural Environment: Our Natural Health Service. Dr William Bird Strategic Health Advisor. Natural England

The intelligent solution. System One Sleep Therapy System uses advanced intelligence to deliver excellent care while making patient management easy

Number of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts)

COPD. Helen Suen & Lexi Smith

Self-Management Plan for COPD

London Strategic Clinical Networks. Quality Standard. Version 1.0 (2015)

Chronic Obstructive Pulmonary Disease (COPD)

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence

Dealing with Asthma in Winter Weather

National COPD Audit Programme

Acute NIV in COPD and what happens next. Dr Rachael Evans PhD Associate Professor, Respiratory Medicine, Glenfield Hospital

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

M J Wildman, 1 C F B Sanderson, 2 J Groves, 3 B C Reeves, 2 J G Ayres, 4 D Harrison, 5 D Young, 6 K Rowan 5. Critical care

Hull and East Riding. Chronic Obstructive Pulmonary. Disease (COPD) Equity Audit

Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation

Acute noninvasive ventilation what s the evidence? Respiratory Medicine Update: Royal College of Physicians & BTS Thu 28 th January 2016

Chronic Obstructive Pulmonary Disease (COPD) Self-management plan

Self-management plan for COPD

Pulmonary Rehab Sheffield Community Active Programmes Team. Ursula Freeman Physiotherapist and Team Leader

Pathway diagrams Annex F

Dear Reader, What was the study about? Why was the research needed? BI NCT

Lung Cancer and Rehabilitation

Community COPD Service Protocol

Intervention and frailty: the Home-based Older People s Exercise (HOPE)Programme

What is the next best step?

Asthma Action Plan and Education

Beverley High School. Asthma Policy

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

Gestione della dispnea nell insufficienza respiratoria end-stage

Putting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Patient Education at the Point of Dispensing Improves Adherence and Increases Sales

Test Bank Pilbeam's Mechanical Ventilation Physiological and Clinical Applications 6th Edition Cairo

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

COPD in primary care: reminder and update

Reference Guide for Group Education

DreamStation. Provider guide

GE Healthcare. Non Invasive Ventilation (NIV) For the Engström Ventilator. Relief, Relax, Recovery

An Outcomes Strategy for COPD and Asthma: NHS Companion Document IMPACT REPORT

INITIATING A COPD CLINIC: PROTOCOL & ASSESSMENT

Emergency Medicine High Velocity Nasal Insufflation (Hi-VNI) VAPOTHERM POCKET GUIDE

Course Handouts & Disclosure

QuickLung Breather Patient Settings

CLINICAL USE CASES FOR RMT

LUNGS IN ACTION: Maintaining Exercise Capacity in Clients with COPD Post Completion of Pulmonary Rehabilitation

COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Transcription:

VitaBreath Helping your COPD patients remain active

COPD: A chronic condition to manage Chronic Obstructive Pulmonary Disease (COPD) is a chronic disorder characterised by consistent airflow obstruction and is associated with persistent and progressive breathlessness, a chronic productive cough and limited exercise capacity. 1 The burden of COPD on the NHS Prevalence COPD makes up approximately 17% of the 15.4 million people in England with a long term condition. 2 Severity COPD remains the 5th most common cause of death in England and Wales. 1 Volume COPD causes 115,000 emergency admissions per year, 24,000 deaths per year and 16,000 deaths within 90 days of admission. 3 Burden on beds One fifth (21%) of bed days used for respiratory disease treatment are due to COPD, accounting for more than one million beds each year in the UK. 1 Goals Reducing Accident & Emergency attendance is a key driver for the NHS in England. Trend There has been a 22% rise in median emergency medical admissions since 2008, with COPD admissions rising by 13%. 4 Symptoms Shortness of breath is the chief complaint for approximately 8% of 999 calls to the ambulance service, and is the third most common emergency call. 5 The goals of effective COPD management are to 6 : Prevent disease progression Relieve symptoms Improve exercise tolerance Improve health status Prevent and treat complications Prevent and treat exacerbations Reduce mortality The World Health Organisation state that an effective management plan for COPD has four components: 1. Assess and monitor 2. Reduce risk factors 3. Manage exacerbations 4. Manage stable COPD All patients with COPD benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnoea (breathlessness) and fatigue

Impact of breathlessness on a COPD patient s life Breathlessness, along with the associated inability to engage in normal activity, is one of the primary and most distressing symptoms for patients with COPD. 7 What is VitaBreath and what are the benefits? VitaBreath is the first handheld bi-level pressure support that can help COPD patients recover more quickly from shortness of breath associated with physical exertion. 9 In a recent study of COPD patients 64% indicated breathlessness impacted their quality of life. 8 How it works Clinical studies show that bi-level pressure support reduces breathlessness and improves exercise performance in patients with moderate to severe COPD. Keeping your patients active VitaBreath helps your patients to manage their chronic shortness of breath whenever and wherever it happens 7 days a week. The benefits of VitaBreath Just a single button and no adjustable settings means there s no set-up required by the clinician, carer or patient. Positive inspiratory pressure reduces the work of breathing Positive expiratory pressure keeps the airway open VitaBreath reduces the severity of breathlessness for COPD patients when used either during or after daily activities, such as walking or climbing the stairs. Light enough to carry (0.5kg) Fits in a personal bag or coat pocket Up to 3 days of use between charges VitaBreath is a non-pharmaceutical solution designed to complement existing COPD therapies, such as medication and pulmonary rehabilitation. Intuitive design means minimal patient training is required and VitaBreath is easy to use when patients need it. Automatically turns off after ten minutes of use to discourage patient reliance on VitaBreath. Patients who regularly experience episodes of dyspnoea (breathlessness) require immediate relief Disposable filters enable multi-patient use in a clinical or pulmonary rehabilitation setting. Dr Robert Angus, Respiratory Consultant Physician Aintree University Hospital Contraindications of VitaBreath: Recent pneumothorax and recent barotrauma to the chest region

Where VitaBreath can fit in with your current COPD management COPD patients who undertake an activity equivalent to walking 60 minutes a day halve their risk of being admitted as an emergency admission irrespective of their severity, nutritional status or respiratory rehabilitation. 10 VitaBreath has been shown to help COPD patients who have been limited by breathlessness walk further. Help to give your patients their confidence back whilst supporting the NHS self-care and prevention agenda. VitaBreath can be built into care packages for the management of shortness of breath at home or in a clinical setting, with the aim of reducing emergency calls and unplanned hospital admissions. VitaBreath is suitable for use in First response vehicles VitaBreath supports your implementation of the COPD NICE Quality Standard Supported discharge for COPD patients is essential. The Quality Standard quotes: People admitted to hospital with a flare-up of COPD are cared for by a respiratory team and are considered for a scheme involving a shorter stay in hospital with extra support at home. 1 The cost of treating a patient with COPD 2 Wait for the device to warm up 3 Breathe in and out through the device until no longer feeling breathless Pulmonary rehabilitation services Acute management in the community Acute management in a clinical setting 502 2729 1 Press the start button DZ21A: length of stay 1 day or less, discharged home 11 DZ21F: with NIV without intubation with CC 11 To arrange a demonstration of VitaBreath, please speak to your local Philips Respironics representative or call 0800 1300 845 Discover more about VitaBreath at philips.co.uk/vitabreath

References: 1. Chronic Obstructive Pulmonary Disease Quality Standard. NICE Quality Standard 10, issued July 2011 https://www.nice.org.uk/guidance/qs10/ chapter/introduction-and-overview 2. Dept of Health Long Term Conditions Compendium of Information Third Edition www.gov.uk/government/uploads/ system/uploads/attachment_data/file/216528/dh_134486.pdf 3. Factsheet 1: Non-invasive ventilation in acute exacerbations of COPD www.england.nhs.uk/ wp-content/uploads/2014/02/rm-fs-6.pdf 4. National COPD Audit Programme. COPD Who cares matters. Executive summary 2015 www.rcplondon.ac.uk/sites/ default/files/nat_copd_audit_prog_secondary_care_clinical_ audit_report_2014_executive_summary_final_web.pdf 5. Shortness of Breath: Emerg Med J 2004; 21: 341-350 doi:10.1136/emj.2004.014878 www. emj.bmj.com/content/21/3/341.full 6. World Health Organisation: Chronic Respiratory Diseases www.who.int/respiratory/copd/burden/en/ 7. Progressive Breathlessness in COPD The role of hyperinflation and its pharmacological management. Primary Care Respiratory Journal (2005) 14, 285 293 8. Behavioral Risk Factor Surveillance System, United States, 2011 http://www.cdc.gov/mmwr/pdf/wk/mm6146.pdf 9. The impact of PEP, CPAP and Bilevel in post exercise recovery from dyspnoea in COPD. Anandi Mahadevan, Laurent Brouqueyre, Chuck Cain, Dr Alan Cropp, Dr Richard ZuWallack. Poster presented at the European Respiratory Society Annual Congress, 1st 5th September 2012 10. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Thorax. 2003 Feb:58(2): 100-5 11. 2014/15 National Tariff Payment System: Annex 5A: National prices 2015 Koninklijke Philips N.V. All rights reserved. Specifications are subject to change without notice. Trademarks are the property of Koninklijke Philips N.V. (Royal Philips) or their respective owners. MLUK00110 CCA 2612 AUG 2015 PN 1125056 MCI 4106835 www.philips.com